PMID- 8874988
OWN - NLM
STAT- MEDLINE
DCOM- 19970116
LR  - 20190512
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 19
IP  - 9
DP  - 1996 Sep
TI  - Hemodynamic effects of creatine phosphate in patients with congestive heart 
      failure: a double-blind comparison trial versus placebo.
PG  - 699-703
AB  - BACKGROUND: The use of metabolic drugs effective in addition to conventional 
      therapy represents a significant challenge in patients with left ventricular 
      dysfunction. HYPOTHESIS: The aim of this double-blind, placebo-controlled study 
      was to investigate the hemodynamic effects of acute intravenous (i.v.) 
      administration of creatine phosphate (CP) and of short-term treatment in patients 
      with congestive heart failure (CHF) from ischemic heart disease (IHD) or dilated 
      cardiomyopathy in addition to conventional therapy. METHODS: We compared the 
      hemodynamic effects of exogenous creatine phosphate (CP) and placebo in a 
      double-blind, crossover design study in 13 hospitalized patients (12 men, 1 
      woman, mean age 52 +/- 8 years) with CHF. All patients were in New York Heart 
      Association (NYHA) class II-III and received conventional pharmacologic therapy 
      for CHF; this was not changed during the study period. The study design consisted 
      of two treatment periods (CP or placebo and placebo or CP, respectively) of 4 
      days each, separated by a 2-day washout interval. The intravenous infusion 
      consisted of 6 g CP or placebo (acute treatment) or 6 g CP or placebo daily for 4 
      days (short-term treatment) diluted in 50 ml of NaCl 0.9%; infusion duration was 
      about 10 min. Mono-bidimensional echocardiographic examination (Hewlett Packard 
      Sonos 1000, with a 2.5 MHz transducer) was performed at baseline, after acute 
      infusion, and 12 h after the end of short-term treatment. Data were analyzed by 
      ANOVA and Student's t-test for paired data; the results obtained after acute and 
      short-term therapy were compared with the baseline values. RESULTS: After placebo 
      therapy, no significant change was observed. The results after treatment with CP 
      showed a significant reduction of end-systolic diameter [baseline: 4.5 +/- 0.6; 
      acute: 4.2 +/- 0.5, (p < 0.001); short-term 4.3 +/- 0.6 cm, (p < 0.05)] and 
      systemic vascular resistance (baseline: 1064.9 +/- 483.7; acute: 947.5 +/- 390.2 
      (p < 0.05); short-term: 950.7 +/- 394.3 dyne-s-cm-5 (p < 0.05); moreover, a 
      significant increase of percent ejection fraction [baseline: 48 +/- 12%; acute 53 
      +/- 12% (p < 0.01); short-term 52 +/- 11% (p < 0.01)], and of percent fractional 
      shortening [baseline: 25 +/- 7; acute 28 +/- 8 (p < 0.05); short-term 28 +/- 7% 
      (p < 0.05)] was observed. CONCLUSION: CP was shown to improve cardiac function, 
      even in the presence of a conventional CHF pharmacologic therapy.
FAU - Ferraro, S
AU  - Ferraro S
AD  - Department of Cardiology, University Federico II, Naples, Italy.
FAU - Codella, C
AU  - Codella C
FAU - Palumbo, F
AU  - Palumbo F
FAU - Desiderio, A
AU  - Desiderio A
FAU - Trimigliozzi, P
AU  - Trimigliozzi P
FAU - Maddalena, G
AU  - Maddalena G
FAU - Chiariello, M
AU  - Chiariello M
LA  - eng
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
RN  - 020IUV4N33 (Phosphocreatine)
SB  - IM
MH  - Cross-Over Studies
MH  - Double-Blind Method
MH  - Echocardiography
MH  - Female
MH  - Heart/drug effects
MH  - Heart Failure/diagnostic imaging/drug therapy/*physiopathology
MH  - Hemodynamics/drug effects
MH  - Humans
MH  - Male
MH  - Phosphocreatine/*pharmacology
EDAT- 1996/09/01 00:00
MHDA- 1996/09/01 00:01
CRDT- 1996/09/01 00:00
PHST- 1996/09/01 00:00 [pubmed]
PHST- 1996/09/01 00:01 [medline]
PHST- 1996/09/01 00:00 [entrez]
AID - 10.1002/clc.4960190905 [doi]
PST - ppublish
SO  - Clin Cardiol. 1996 Sep;19(9):699-703. doi: 10.1002/clc.4960190905.